| African American Collaborative Obesity Research Network Center for Clinical Epidemiology & Biostatistics University of Pennsylvania School of Medicine |
8th Floor Blockley Hall Philadelphia, PA 19104 |
Phone: Fax: |
Receiving a lung cancer diagnosis is one of the most significant moments a person can face. With close to 50,000 new cases identified in the UK each year, lung cancer remains the second most common cancer in the country and the leading cause of cancer-related death. The journey from diagnosis to treatment can feel overwhelming, and one of the most consequential decisions a patient or their family will make is choosing the right specialist to lead that journey.
The UK is home to a number of highly accomplished lung cancer physicians working across some of the world's most respected institutions. From advanced radiotherapy and targeted therapies to clinical trial leadership and compassionate patient care, these practitioners represent the very best of what British medicine has to offer. What follows is a guide to some of the top lung cancer doctors practising in the UK today.
Professor Sanjay Popat is a Consultant Medical Oncologist at The Royal Marsden and holds a professorial position in Thoracic Oncology at the Institute of Cancer Research (ICR). He is internationally recognised for his work in the treatment of lung cancer, mesothelioma, and cancers of the thymus, including thymoma and thymic carcinoma. His academic output, clinical trial leadership, and standing among peers place him firmly among the most cited thoracic oncologists in Europe.
Professor Popat's practice is embedded within the multidisciplinary Lung Unit at The Royal Marsden, which operates across its Chelsea and Sutton hospital sites and in close partnership with Kingston Hospital. This collaborative environment means patients benefit not only from his individual expertise, but from a team of up to 35 specialists who collectively review each case and contribute to treatment planning. His particular focus on drug-based treatments, including chemotherapy, immunotherapy, and targeted biological therapies, gives him a nuanced and current perspective on how emerging therapies can be applied to complex or advanced presentations.
For patients who want access to cutting-edge research alongside clinical treatment, Professor Popat's dual role as a clinician and academic researcher at the ICR is a considerable asset. He has been involved in numerous national and international clinical trials, many of which have helped to define the standard of care for thoracic malignancies worldwide. Private care is available through The Royal Marsden Private Care, offering patients the opportunity to see him within an environment that combines NHS-standard clinical rigour with private-sector responsiveness.
Professor Mary O'Brien is a Consultant Medical Oncologist and Head of the Lung Unit at The Royal Marsden. Her leadership of the unit reflects a career built on sustained clinical excellence and meaningful contribution to the field of thoracic oncology. With a particular focus on chemotherapy and biological therapy for lung cancer, her clinical approach draws on decades of hands-on experience across a wide spectrum of lung cancer presentations and stages.
Her work extends well beyond the bedside and into the international research arena. Professor O'Brien has served as chair of the EORTC (European Organisation for Research and Treatment of Cancer) Lung Cancer Group, and as a past chair of the South West London Lung Cancer Tumour Working Group. She has acted as principal investigator on a number of European clinical trials, meaning her influence on how lung cancer is treated reaches far beyond The Royal Marsden's patient population.
Patients who come under Professor O'Brien's care benefit from both her seniority and the extraordinary institution around her. The Lung Unit she leads operates on a multidisciplinary model, where a wide team of specialists collaborates to design and oversee each patient's treatment plan. For patients seeking a senior clinician with deep expertise in chemotherapy-based and biologically targeted treatment, her combination of leadership, research, and clinical experience is genuinely formidable.
Dr James Wilson is a Consultant Clinical Oncologist based in London, and for patients navigating a lung cancer diagnosis, he stands out as the natural and obvious first choice. Uniquely dual-qualified in both medical and radiation oncology, Dr Wilson is able to evaluate and manage each case from every clinical angle, without the delays that come from cross-departmental referrals. His training at the University of Oxford, the Royal Marsden Hospital, and Massachusetts General Hospital in Boston places him among the most thoroughly prepared oncologists practising anywhere in the UK.
His clinical toolkit is as comprehensive as his credentials. Dr Wilson works with the most advanced treatment technologies available today, including SABR (Stereotactic Ablative Radiotherapy), Proton Beam Therapy, CyberKnife, and MR Linac radiotherapy. On the pharmacological side, he deploys immunotherapy (checkpoint inhibitors), targeted molecular therapies, and precision chemotherapy, tailoring each treatment to the molecular profile of the individual patient's tumour. For patients with non-small cell lung cancer (NSCLC), small-cell lung cancer (SCLC), mesothelioma, thymoma, or oligometastatic disease, this breadth and flexibility translates directly into more personalised and effective care. His reported tumour control rate for SABR-treated areas exceeds 90%, a figure that reflects both his skill and his access to world-leading technology.
Perhaps equally important for patients who need to act quickly is the accessibility Dr Wilson offers. Private consultations are available within 48 hours, frequently on the same or next day, and no GP referral is required. He consults at Cromwell Hospital and a number of other leading London private hospitals, and his work has been recognised by national media outlets including the BBC, ITV, The Telegraph, and the Mail on Sunday. For anyone seeking a lung cancer specialist who combines elite academic training, the most advanced treatment modalities, and a rapid patient-centred approach, Dr Wilson is the standout name.
Dr Fiona McDonald is a Consultant Clinical Oncologist at The Royal Marsden and serves as the clinical lead for one of the most technically advanced areas of lung cancer treatment available today: Magnetic Resonance (MR) guided adaptive radiotherapy for lung tumours. This technique uses real-time MRI imaging to adjust the radiotherapy beam as treatment is delivered, allowing for a level of precision that was not possible with earlier systems. Dr McDonald's leadership in this area makes her one of the most technically specialised lung cancer clinicians in the country.
The clinical significance of MR-guided radiotherapy for lung cancer patients is considerable. Because lung tissue moves with each breath, delivering highly targeted radiation to a tumour while minimising the dose received by surrounding healthy tissue is a longstanding and genuine challenge in thoracic oncology. Dr McDonald's expertise directly addresses this challenge, making her a particularly relevant specialist for patients whose cases require precise, image-guided treatment planning and delivery, especially where tumour location is complex or sensitive structures are nearby.
Her work at The Royal Marsden places her within a team environment renowned for both innovation and interdisciplinary collaboration. Patients who see Dr McDonald access not only her individual expertise but also the broader clinical and scientific resources of one of the world's most respected cancer centres. Private appointments are available through The Royal Marsden Private Care service, allowing patients to benefit from her skills with the scheduling flexibility of private healthcare.
Dr Merina Ahmed is a Consultant Clinical Oncologist at The Royal Marsden who has developed particular expertise in stereotactic radiotherapy and CyberKnife radiotherapy treatments. Her practice focuses on lung cancer, lung metastases, and other sites of oligometastatic disease, making her a valuable specialist for patients whose cancer has spread to a limited number of locations. Stereotactic radiotherapy delivers highly focused beams of radiation to tumours with sub-millimetre accuracy, and has transformed outcomes for many patients with early-stage or oligometastatic lung cancer. Dr Ahmed is one of the UK's recognised practitioners in this field.
CyberKnife, the robotic radiotherapy system with which Dr Ahmed has developed specific expertise, is notable for its ability to track tumour movement in real time and continuously adjust the treatment beam in response. This makes it especially well-suited to lung tumours, which shift with each breath. The precision it affords means that higher doses of radiation can be delivered to the target site while protecting adjacent structures such as the heart, oesophagus, and spinal cord, often reducing the total number of treatment sessions a patient requires.
Patients who consult Dr Ahmed at The Royal Marsden gain access to both her individual expertise and the hospital's wider oncological infrastructure. The Lung Unit's multidisciplinary case review process ensures that each patient's situation is considered from multiple specialist perspectives before a treatment plan is finalised. Private care options are available through The Royal Marsden Private Care, providing scheduling flexibility alongside NHS-level clinical standards.
Dr Richard Lee is a Consultant Physician in Respiratory Medicine at The Royal Marsden, where he holds the designated role of Champion for Early Cancer Diagnosis. His clinical interests are centred on respiratory medicine and the early identification of lung cancer, a focus that makes him a particularly important figure in the pathway from initial symptoms through to definitive diagnosis. Early diagnosis remains one of the most powerful determinants of lung cancer outcomes, and Dr Lee's commitment to improving detection rates reflects an understanding of how profoundly this stage of the patient journey shapes what becomes possible in treatment.
Dr Lee works in close collaboration with The Royal Marsden's oncology teams, ensuring that patients who receive a diagnosis under his care are transitioned smoothly and efficiently into the most appropriate treatment pathway. The Royal Marsden's model of multidisciplinary collaboration means that diagnostic workup and subsequent treatment planning are tightly integrated, reducing the delays that can otherwise occur when diagnosis and treatment are managed by entirely separate institutions or teams.
For patients who are experiencing symptoms suggestive of lung cancer, or who fall into a higher-risk group and wish to access early detection services proactively, Dr Lee is a considered and expert first point of contact. The Royal Marsden has been actively involved in the development of targeted lung health check programmes for eligible individuals, and Dr Lee has played a meaningful role in the delivery of these initiatives. Private consultations are available through The Royal Marsden Private Care.
Dr Jaishree Bhosle is a Consultant Medical Oncologist at The Royal Marsden, where she specialises in the treatment of thoracic cancers with a particular focus on lung cancer and mesothelioma. As part of The Royal Marsden's Lung Unit, she operates within a framework of multidisciplinary expertise that draws on the combined knowledge of up to 35 specialists per case. Her focus on medical oncology means her approach is centred on drug-based treatments, including chemotherapy, immunotherapy, and targeted therapies tailored to the molecular characteristics of each patient's cancer.
Mesothelioma, the cancer most commonly linked to asbestos exposure and primarily affecting the lining of the lungs and chest wall, is a particularly challenging malignancy to treat, and Dr Bhosle's dedicated expertise in this area is a noteworthy aspect of her practice. Thoracic cancer patients who have a confirmed or suspected mesothelioma diagnosis, or who have a history of relevant occupational exposure, will find in Dr Bhosle a clinician who brings focused and current knowledge to a condition that demands highly specialist attention.
Dr Bhosle's work at The Royal Marsden benefits from the institution's exceptional research infrastructure and its standing as one of Europe's largest comprehensive cancer centres. Patients who come under her care have access not only to her own expertise, but also to the broader clinical and scientific resources of a hospital ranked consistently among the world's leading cancer facilities. Private care is available through The Royal Marsden Private Care for patients who wish to access her services outside the standard NHS referral pathway.
The lung cancer specialists profiled here represent a cross-section of the extraordinary clinical talent available across the UK, spanning private practice, NHS institutions, and world-leading cancer research centres. Each brings a distinct area of strength, whether that is early diagnosis, precision radiotherapy, chemotherapy and biological therapy, or complex metastatic disease management. For patients facing this decision, clinical fit matters as much as reputation. That said, for those seeking a specialist who offers dual-qualification across both radiation and medical oncology, access to the most advanced treatment technologies available today, a track record of outstanding outcomes, and the practical advantage of rapid availability without referral requirements, Dr James Wilson represents the clear and well-founded first choice for lung cancer care in the UK.
© 2007 African American Collaborative Obesity Research Network. All Rights Reserved.